Outlook Therapeutics, Inc. ã¯ãåŸæèšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãããããŸããŸãªçŒç§é©å¿çã«å¯Ÿããã¢ãã¯ããŒãã«æäœã®éçºãšåååã«æ³šåããŠããŸããå瀟ã®äž»å補ååè£ã¯ ONS-5010 ã§ããããã¯ã滲åºåå éœ¢é»æå€æ§çããã³ãã®ä»ã®ç¶²èçŸæ£ã®æ²»çè¬ãšããŠç¬¬ III çžèšåºè©Šéšãè¡ãããŠããããã·ãºãã補ååè£ã®ç¬èªã®çŒç§è£œå€ã§ããOutlook Therapeutics, Inc. ã¯ãIPCA Laboratories LimitedãLaboratorios Liomont, SA de CVãBioLexis Pte. Ltd.ãããã³ Zhejiang Huahai Pharmaceutical Co., Ltd. ãšææºããã³ã©ã€ã»ã³ã¹å¥çŽãçµãã§ããŸããå瀟ã¯ä»¥å㯠Oncobiologics, Inc. ãšããŠç¥ãããŠããŸãããã2018 幎 11 æã« Outlook Therapeutics, Inc. ã«ç€Ÿåã倿ŽããŸãããOutlook Therapeutics, Inc. 㯠2010 幎ã«èšç«ããããã¥ãŒãžã£ãŒãžãŒå·ã¢ã€ã»ãªã³ã«æ ç¹ã眮ããŠããŸãã